Circulating apoptotic proteins are increased in long-term disease-free breast cancer survivors
Key result
Circulating apoptosis markers were higher in long-term disease-free breast cancer survivors than in healthy controls, particularly after high-dose myeloablative chemotherapy.
Why the study?
Are circulating apoptotic proteins increased in long-term disease-free breast cancer survivors and associated with cardiotoxicity?
Population
34 long-term disease-free breast cancer survivors and 12 healthy age-matched women.
Comparison
Adjuvant chemoradiotherapy consisting of five… vs 12 healthy age-matched women.
Design
Cohort
Follow-up
median 6.0 years
Authors
Discussion
Loading...
Member takes
Implication
Elevated apoptosis markers in survivors lack clear cardiotoxicity link; leaves open their role in surveillance pending prospective data.
Study Design
Type
Case-Control (n=46)
Structured PICO
Are circulating apoptotic proteins increased in long-term disease-free breast cancer survivors and associated with cardiotoxicity?
P
Population
46 women, comprising 34 long-term disease-free breast cancer survivors with a median 6.0 years follow-up and 12 healthy age-matched controls.
E
Exposure
Adjuvant chemoradiotherapy consisting of five cycles fluorouracil, epirubicin (90 mg/m2), cyclophosphamide (FEC) (n=14) or four cycles FEC followed by myeloablation with high-dose carboplatin, cyclophosphamide, thiotepa (n=20), preceding irradiation and tamoxifen.
C
Comparator
12 healthy age-matched women.
O
Outcome
Levels of circulating soluble apoptosis-related proteins (TNF alpha, sTNF-R1/2, sFas, sFas ligand, sTRAIL) and inflammation markers.surrogate
Long-term disease-free breast cancer survivors treated with adjuvant chemoradiotherapy exhibit increased circulating apoptotic proteins, particularly after myeloablative chemotherapy, though without clear association with cardiac dysfunction.
Cite This Study
Perik et al. (2006) conducted a case-control in Long-term disease-free breast cancer (n=46). Adjuvant chemoradiotherapy vs. Healthy age-matched women was evaluated on Circulating soluble apoptosis-related proteins and inflammation markers. Circulating apoptosis markers were higher in long-term disease-free breast cancer survivors than in healthy controls, particularly after high-dose myeloablative chemotherapy.